Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA cancels meeting on J&J’s ceftobiprole

Executive Summary

FDA cancels the Anti-Infective Drugs Advisory Committee meeting scheduled for Feb. 28 to discuss Johnson & Johnson's NDA for the broad-spectrum cephalosporin antibiotic ceftobiprole. The committee will still meet on Feb. 27 to discuss Theravance's telavancin for the treatment of complicated skin and skin structure infection (1"The Pink Sheet," Jan. 14, 2008, In Brief)...

You may also be interested in...



Advisory committee to review two antibiotics

The Anti-Infective Drugs Advisory Committee will review Johnson & Johnson's ceftobiprole medocaril Feb. 27, and Theravance/Astella's telavancin Feb. 28. Committee discussion may center on the use of non-inferiority studies to support the applications for the treatment of complicated skin and skin structure infections; such designs are discouraged by draft FDA guidance, and the agency may want reassurance on efficacy questions (1"The Pink Sheet" Oct. 22, 2007, p. 17)...

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

Gilead Sees Room For Trodelvy In European Markets

Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.

UsernamePublicRestriction

Register

PS049308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel